If you have been reading about PPARδ agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-11. Numbers and descriptions here follow the published literature rather than marketing material.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
=== Audiovisual work === After military service in World War I, Jones returned to Hallock where he worked as a mechanic while learning about electronics. Jones built a transmitter for the town's first radio station. He also invented a device to combine sound with motion pictures. This attracted the attention of local entrepreneur Joseph A. Numero of Minneapolis, Minnesota. Numero owned a company that manufactured audio equipment called Ultraphone Sound Systems Inc. and was later renamed Cinema Supplies Inc. He hired Jones in 1927 as an electrical engineer to improve the audio equipment made by his firm. Jones worked on converting silent movie projectors into audiovisual projectors. He also patented a ticket-dispensing machine for movie theaters.
Tofu flavor is generally described as bland, which is generated during the grinding and cooking process, and either a "hot grind" or a "cold grind" can be used to influence the taste. The hot grind method reduces the beany flavor by inactivating the lipoxygenase enzyme in the soy protein that is known to generate off flavors. Eliminating these flavors makes tofu that is "bland". If a cold grind is used lipoxygenase remains and produces the aldehyde, alcohol, and ester volatile compounds that create beany notes.
These events, along with the relationship between Mandela and Pienaar, were the subject of a 2008 book by John Carlin, Playing the Enemy: Nelson Mandela and the Game that Made a Nation, that spotlights the role of the 1995 Cup win in post-apartheid South Africa. Carlin sold the film rights to Morgan Freeman. The result was the 2009 film Invictus, directed by Clint Eastwood and starring Freeman as Nelson Mandela and Matt Damon as Pienaar.
=== Buoyancy control === Surface-supplied divers may be required to work in mid-water or on the bottom. They must be able to stay down without effort, and this usually requires weighting. When working in mid-water the diver may wish to be neutrally buoyant or negative, and when working on the bottom, will usually want to be several kilograms negative. The only time the diver may want to be positively buoyant is when on the surface or during a limited range of emergencies where uncontrolled ascent is less life-threatening than remaining under water. Surface-supplied divers generally have a secure supply of breathing gas, and there are very few occasions where weights should be jettisoned, so in most cases the surface-supplied diver weighting arrangement does not provide for quick release. On those occasions when surface supplied divers need variable buoyancy, it may be provided by inflation of the dry suit, if used, or by a buoyancy control device similar in principle to those used by scuba divers, or both.
Sources: en.wikipedia.org
Mayer's reagent is an alkaloidal precipitating reagent used for the detection of alkaloids in natural products. Mayer's reagent is freshly prepared by dissolving a mixture of mercuric chloride (1.36 g) and of potassium iodide (5.00 g) in water (100.0 ml). Most alkaloids are precipitated from neutral or slightly acidic solution by Mayer's reagent (potassiomercuric iodide solution) to give a cream coloured precipitate. This test was invented by and named after the German chemist Julius Robert Von Mayer (1814–1878). Can be used as a visualization reagent in thin-layer chromatography (TLC) for the detection of alkaloids.
6-carboxytetrahydropterin synthase (EC 4.1.2.50, CPH4 synthase, queD (gene), ToyB, ykvK (gene)) is an enzyme with systematic name 7,8-dihydroneopterin 3'-triphosphate acetaldehyde-lyase (6-carboxy-5,6,7,8-tetrahydropterin and triphosphate-forming). This enzyme catalyses the following reversible chemical reaction. 7,8-dihydroneopterin 3′-triphosphate + H2O ⇌ 6-carboxy-5,6,7,8-tetrahydropterin + acetaldehyde + triphosphate This enzyme binds Zn2+. It is isolated from the bacteria Bacillus subtilis and Escherichia coli. The stimulation is part of the biosynthesis pathway of queuosine. The enzyme from Escherichia coli can also convert 6-pyruvoyl-5,6,7,8-tetrahydropterin and sepiapterin to 6-carboxy-5,6,7,8-tetrahydropterin. Media related to 6-carboxytetrahydropterin synthase at Wikimedia Commons 6-carboxytetrahydropterin+synthase at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
The NK-92 cell line is an immortalised cell line that has the characteristics of a type of immune cell found in human blood called 'natural killer' (NK) cells. Blood NK cells and NK-92 cells recognize and attack cancer cells as well as cells that have been infected with a virus, bacteria, or fungus. NK-92 cells were first isolated in 1992 in the laboratory of Hans Klingemann at the British Columbia Cancer Agency in Vancouver, Canada, from a patient who had a rare NK cell non-Hodgkin-lymphoma. These cells were subsequently developed into a continuously growing cell line. NK-92 cells are distinguished by their suitability for expansion to large numbers, ability to consistently kill cancer cells and testing in clinical trials. When NK-92 cells recognize a cancerous or infected cell, they secrete perforin that opens holes into the diseased cells and releases granzymes that kill the target cells. NK-92 cells are also capable of producing cytokines such as tumor necrosis factor alpha (TNF-a) and interferon gamma (IFN-y), which stimulates proliferation and activation of other immune cells.
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.